UBS Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
UBS Group's BEAM Position: Q3 2026 in Review
UBS Group increased its Beam Therapeutics (BEAM) stake by 6.2% in Q3 2026, buying an estimated $994K and bringing the position to 610,513 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2979.
UBS Group first reported a position in BEAM in Q1 2020 and has held it in 27 quarters since. The position peaked at $45.1M in Q4 2024. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- UBS Group held 610,513 shares of Beam Therapeutics worth $14.9M as of Q3 2026.
- UBS Group bought 35,699 Beam Therapeutics shares in Q3 2026, an estimated $994K.
- Beam Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2979 holding.
- UBS Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 27 quarters since.
- UBS Group's Beam Therapeutics position peaked at $45.1M in Q4 2024.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.